Drugs / Visbiome
Visbiome
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02441244 | Nov 2015 → Dec 2016 | HIV infectious disease | University Health Network, Toronto | Terminated | No outcome recorded |
| Phase 2 | NCT02441231 | Nov 2015 → May 2019 | HIV infectious disease | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03078530 | Sep 2013 → May 2018 | persian gulf syndrome | Ashok Tuteja | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06898788 Comparator | May 2025 → Aug 2026 overdue | depressive disorder | University of California, San Francisco | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Visbiome | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03078530 ↗ |
| Known as | De Simone Formulation Probiotic | “De Simone Formulation Probiotic (DSFP; "Visbiome" commercially) or placebo for 48 weeks” PMID 34693932 ↗ Feb 2022 |
| Known as | DSFP | “De Simone Formulation Probiotic (DSFP; "Visbiome" commercially) or placebo for 48 weeks” PMID 34693932 ↗ Feb 2022 |
| Modality | Other / unclassified | “Probiotic Visbiome consists of a high potency blend of eight different probiotics.” NCT02441231 ↗ |
| Route | Oral | “Visbiome 450 billion CFU (sachet) twice daily” NCT06898788 ↗ |